A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

You may be eligible if

• Inclusion:
• Diagnosis of Crohn's disease
• CDAI score at baseline of between 220 and 450
• Normal laboratory parameters
• Willing and able to give informed consent
• Exclusion:
• Diagnosis of ulcerative colitis
• Women cannot be pregnant or breastfeeding
• No previous use of infliximab or other anti-TNF antagonists
• No previous history of tuberculosis or listeria infection
• No previous history of cancer other than successfully treated skin cancer